Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: TSE:CXR
- CUSIP: N/A
- Web: concordiarx.com
Capitalization:- Market Cap: C$76.2 million
- Outstanding Shares: 51,143,000
Average Prices:- 50 Day Moving Avg: C$1.62
- 200 Day Moving Avg: C$1.89
- 52 Week Range: C$1.41 - C$7.39
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: C$677.25 million
- Price / Sales: 0.11
- Book Value: C($27.60) per share
- Price / Book: -0.05
Profitability:- EBIDTA: C$326.58 million
- Net Margins: -628.57%
- Return on Assets: -130.11%
Misc:- Average Volume: 193,684 shs.
- Short Ratio: 0.8
Frequently Asked Questions for Concordia International Corp (TSE:CXR)
What is Concordia International Corp's stock symbol?
Concordia International Corp trades on the Tornton Stock Exchange (TSX) under the ticker symbol "CXR."
How were Concordia International Corp's earnings last quarter?
Concordia International Corp (TSE:CXR) released its quarterly earnings data on Thursday, August, 13th. The company reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.06 by $0.02. The company earned $95.34 million during the quarter, compared to analyst estimates of $87.41 million. View Concordia International Corp's Earnings History.
When will Concordia International Corp make its next earnings announcement?
Where is Concordia International Corp's stock going? Where will Concordia International Corp's stock price be in 2017?
4 brokerages have issued 12-month price objectives for Concordia International Corp's shares. Their predictions range from C$13.50 to C$13.50. On average, they expect Concordia International Corp's share price to reach C$13.50 in the next twelve months. View Analyst Ratings for Concordia International Corp.
Who are some of Concordia International Corp's key competitors?
Some companies that are related to Concordia International Corp include XOMA Corporation (XOMA), ContraFect Corporation (CFRX), Protalix Biotherapeutics (PLX), Trillium Therapeutics (TRIL), Aevi Genomic Medicine (GNMX), Ohr Pharmaceuticals (OHRP), Can Fite Biopharma Ltd (CANF), Can Fite Biopharma Ltd (CANF), Soligenix (SNGX), Soligenix (SNGX), Mateon Therapeutics (MATN), Senesco Technologies (SVON), Windtree Therapeutics (WINT), Affymax (AFFY), CSL Limited (CSL), Cubist Pharmaceuticals (CBST), Dendreon (DNDN) and DNIB Unwind (BIND).
Who are Concordia International Corp's key executives?
Concordia International Corp's management team includes the folowing people:
- Wayne Kreppner, President, Chief Operating Officer
- Allan Oberman, Chief Executive Officer, Director
- David J. Price, Chief Financial Officer
- Graeme Duncan, President - Company's International Segment
- Arijit Mookerjee, Managing Director, Chief Financial Officer - Operations
- Adeel Ahmad, Chief Financial Officer of AMCo
- Francesco Tallarico, Chief Legal Officer and Secretary
- Jordan M. Kupinsky J.D., Non-Executive Independent Chairman of the Board
- Douglas N. Deeth, Independent Director
- Rochelle Fuhrmann, Independent Director
How do I buy Concordia International Corp stock?
Shares of Concordia International Corp and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Concordia International Corp's stock price today?
One share of Concordia International Corp stock can currently be purchased for approximately C$1.49.
MarketBeat Community Rating for Concordia International Corp (TSE CXR)MarketBeat's community ratings are surveys of what our community members think about Concordia International Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Concordia International Corp (TSE:CXR) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Sell Ratings |
| Consensus Rating: | Sell (Score: 1.00) |
| Consensus Price Target: | C$13.50 |
Analysts' Ratings History for Concordia International Corp (TSE:CXR)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 3/16/2017 | Scotiabank | Reiterated Rating | Underperform | |  |
| 2/9/2017 | TD Securities | Downgrade | Hold -> Reduce | | |
| 12/8/2016 | Royal Bank Of Canada | Downgrade | Sector Perform -> Underperform | | |
| 11/7/2016 | Bloom Burton | Downgrade | Hold -> Sell | | |
| 8/15/2016 | Goldman Sachs Group, Inc. (The) | Lower Price Target | | C$34.00 -> C$17.00 | |
| 8/15/2016 | CIBC | Downgrade | Sector Perform -> Underperform | | |
| 3/21/2016 | Dundee Securities | Lower Price Target | | C$62.00 -> C$60.00 | |
| 12/3/2015 | Mackie | Downgrade | Hold | | |
(Data available from 9/25/2015 forward)
Earnings History for Concordia International Corp (TSE:CXR)Earnings History by Quarter for Concordia International Corp (TSE CXR)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | | | | | | | |
| 8/13/2015 | Q2 | C$1.06 | C$1.04 | C$87.41 million | C$95.34 million | View | Listen | |
| 8/13/2014 | | C$0.19 | C($0.03) | C$24.42 million | C$28.49 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Concordia International Corp (TSE:CXR)Current Year EPS Consensus Estimate: $0.66 EPS
Dividend History by Quarter for Concordia International Corp (TSE CXR)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 7/13/2016 | Quarterly | $0.08 | 1.14% | 7/13/2016 | 7/29/2016 | 7/29/2016 |
| 4/13/2016 | Quarterly | $0.08 | 0.95% | 4/13/2016 | 4/29/2016 | 4/29/2016 |
| 1/13/2016 | Quarterly | $0.08 | 0.53% | 1/13/2016 | 1/29/2016 | 1/29/2016 |
| 10/13/2015 | Quarterly | $0.08 | 0.62% | 10/13/2015 | 10/30/2015 | 10/30/2015 |
| 7/13/2015 | Quarterly | $0.08 | 0.32% | 7/13/2015 | 7/31/2015 | 7/31/2015 |
| 4/13/2015 | Quarterly | $0.08 | 0.35% | 4/13/2015 | 4/30/2015 | 4/30/2015 |
| 1/13/2015 | Quarterly | $0.08 | 0.61% | 1/13/2015 | 1/31/2015 | 1/31/2015 |
| 10/10/2014 | Quarterly | $0.08 | 0.76% | 10/10/2014 | 10/31/2014 | 10/31/2014 |
| 7/11/2014 | Quarterly | $0.08 | 0.92% | 7/11/2014 | 7/31/2014 | 7/31/2014 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Concordia International Corp (TSE:CXR)Insider Trades by Quarter for Concordia International Corp (TSE:CXR)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/25/2017 | Erin Colleen O'neil | Director | Sell | 191 | C$1.74 | C$332.34 | |
| 5/16/2017 | Graeme Neville Duncan | Director | Sell | 7,065 | C$1.91 | C$13,494.15 | |
| 2/1/2016 | Mark Laurence Thompson | Director | Buy | 60 | C$28.77 | C$1,726.20 | |
| 11/17/2015 | Rochelle Fuhrmann | Director | Buy | 2,000 | C$31.67 | C$63,340.00 | |
| 11/17/2015 | Wayne Walter Kreppner | Insider | Buy | 3,000 | C$43.67 | C$131,010.00 | |
| 11/16/2015 | Mark Laurence Thompson | Director | Buy | 23,150 | C$43.36 | C$1,003,702.98 | |
| 10/27/2015 | Edward Borkowski | Director | Buy | 4,000 | C$30.43 | C$121,720.00 | |
| 7/23/2015 | Jordan Kupinsky | Director | Sell | 43,000 | C$103.70 | C$4,459,272.00 | |
| 7/17/2015 | Wayne Walter Kreppner | Insider | Sell | 4,800 | C$103.00 | C$494,400.00 | |
| 7/3/2015 | Jordan Kupinsky | Director | Sell | 10,800 | C$92.21 | C$995,884.20 | |
| 7/2/2015 | Jordan Kupinsky | Director | Sell | 45,900 | C$92.05 | C$4,224,934.35 | |
| 6/26/2015 | Robert Steven Altman | Insider | Sell | 62,500 | C$93.93 | C$5,870,893.75 | |
| 6/22/2015 | John-Michel Huss | Director | Sell | 5,000 | C$92.00 | C$460,000.00 | |
| 6/19/2015 | John-Michel Huss | Director | Sell | 4,300 | C$90.00 | C$387,000.00 | |
| 6/11/2015 | John-Michel Huss | Director | Sell | 4,500 | C$90.02 | C$405,076.50 | |
| 5/27/2015 | Saldanha Adrian De | Insider | Buy | 1,000 | C$80.61 | C$80,610.00 | |
| 5/19/2015 | Adeel Ahmad | Insider | Sell | 25,000 | C$83.80 | C$2,094,890.00 | |
| 10/31/2014 | James Christopher Reebals | Director | Sell | 7,500 | C$37.25 | C$279,360.75 | |
| 10/30/2014 | James Christopher Reebals | Director | Sell | 7,500 | C$37.06 | C$277,926.75 | |
| 10/29/2014 | James Christopher Reebals | Director | Sell | 5,000 | C$37.07 | C$185,336.50 | |
(Data available from 1/1/2013 forward)
Headline Trends for Concordia International Corp (TSE:CXR)
Latest Headlines for Concordia International Corp (TSE:CXR)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to Concordia International Corp. : September 6, 2017
finance.yahoo.com - September 6 at 12:19 AM |
 | Concordia International Corp. Announces Release Date for DELIVER Strategy - PR Newswire (press release)
www.prnewswire.com - September 1 at 11:00 PM |
 | Canadian Stocks Are Rising On Strong GDP Data - Canadian Commentary
www.nasdaq.com - August 31 at 5:37 PM |
| Concordia International Corp. :CXR-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 18, 2017
finance.yahoo.com - August 18 at 5:40 PM |
| RedHill Biopharma Announces US Commercialization Agreement for FDA-Approved GI Product Esomeprazole ... - Nasdaq
www.nasdaq.com - August 17 at 4:32 PM |
 | SHAREHOLDER ALERT: Morganti Legal, PC Advises Shareholders of Concordia International Corp. of a Motion ... - Business Wire (press release)
www.businesswire.com - August 15 at 6:24 PM |
| Edited Transcript of CXR.TO earnings conference call or presentation 11-Aug-17 12:30pm GMT
finance.yahoo.com - August 11 at 11:12 PM |
 | Concordia International Corp (TSE:CXR) Set to Announce Earnings on Friday
www.americanbankingnews.com - August 4 at 7:12 AM |
| Concordia International Corp. :CXR-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017
finance.yahoo.com - August 3 at 7:15 PM |
| Short seller Cohodes hits Canada again with latest target -Exchange Income
www.nasdaq.com - July 5 at 6:28 PM |
 | Concordia Shares Lead TSX Gainers on Corporate Update
www.baystreet.ca - June 22 at 10:32 AM |
| Canadian Healthcare Stocks Under Review Concordia International, ProMetic Life Sciences, Theratechnologies, and Cardiome Pharma
finance.yahoo.com - June 9 at 8:27 AM |
| Concordia International Corp. Announces Results of First CMA Stop/Go Decision - PR Newswire (press release)
www.prnewswire.com - May 31 at 9:39 PM |
| Concordia International Corp (CXR) Given Consensus Rating of "Sell" by Analysts
www.americanbankingnews.com - May 23 at 7:48 AM |
| Concordia International Corp (CXR) Director Graeme Neville Duncan Sells 7,065 Shares
www.americanbankingnews.com - May 17 at 8:34 PM |
| Concordia International Corp (CXR) PT Lowered to C$0.35
www.americanbankingnews.com - May 12 at 1:02 PM |
| Edited Transcript of CXR.TO earnings conference call or presentation 10-May-17 12:30pm GMT
finance.yahoo.com - May 10 at 9:49 PM |
| Concordia International Corp. Announces Two New Appointments to ... - PR Newswire (press release)
www.prnewswire.com - May 4 at 8:02 AM |
| Concordia International Corp. Announces Release Date for First Quarter 2017 Results
finance.yahoo.com - May 2 at 8:03 PM |
| Concordia International Corp (CXR) Given Consensus Recommendation of "Sell" by Analysts
www.americanbankingnews.com - April 28 at 10:37 AM |
| Concordia International Appoints David Price as Chief Financial Officer
finance.yahoo.com - April 27 at 1:48 AM |
| Canadian Stocks Are Extending Recent Losses - Canadian Commentary
www.nasdaq.com - April 13 at 11:46 AM |
| Concordia International Corp (CXR) Given Average Rating of "Sell" by Analysts
www.americanbankingnews.com - April 3 at 1:42 PM |
| Canadian Stocks Are Paring Early Gains - Canadian Commentary
www.nasdaq.com - March 17 at 9:58 PM |
| Stocks Rally On Oil Rebound, Sober Fed -- Canadian Commentary
www.nasdaq.com - March 15 at 5:04 PM |
| Concordia International Announces Fourth Quarter and Fiscal 2016 Results
finance.yahoo.com - March 15 at 9:47 AM |
| Q4 2016 Concordia International Corp Earnings Release - Before Market Open
biz.yahoo.com - March 15 at 9:47 AM |
| RedHill Biopharma's Co-Promotion Partner Concordia Announces ... - Nasdaq
www.nasdaq.com - March 7 at 4:34 PM |
| Concordia International Corp. Grant of Treble Damages Further Vindicates Marketing Rights of its Donnatal® Brand - Yahoo Finance
finance.yahoo.com - March 7 at 4:34 PM |
 | Profile: Concordia International Corp (CXR.TO)
www.reuters.com - February 7 at 10:47 PM |
| Canadian Stocks Are Extending Their Losses In Early Trade - Canadian Commentary - Nasdaq
www.nasdaq.com - January 31 at 5:15 PM |
| Concordia International Corp. Announces Leadership Transition at International Segment
finance.yahoo.com - December 28 at 11:59 AM |
 | TSX Slightly Higher, Blackberry Makes Bet On Self-driving Cars
www.rttnews.com - December 20 at 5:23 PM |
Concordia International Corp (CXR) Chart for Monday, September, 25, 2017
